New Trial(s) on Antiedema Treatment in Stroke?

To the Editor:

We read with interest the Controversies in Stroke on steroids, and appreciated both Dr Norris’ and Dr Poungvarin’s papers. We fully agree with the conclusion of Drs Davis and Donnan, in that when no commercial attraction exists for some treatment, then only high-quality, investigator-driven trials are possible. However, we wish to stress the fact that if someone is interested in planning such a trial on antiedema treatment for stroke patients, he or she should first look at the available evidence and choose the most promising drug, with the higher probability of a positive result. Therefore, looking at the Cochrane Library, it seems to us that it is glycerol, and not steroids, that should be the first choice for a new trial on antiedema treatment in acute stroke. In fact, glycerol has been studied in ten trials with a total of 945 patients (almost double the number as compared with steroids). There was a nonsignificant reduction in the odds ratio (OR) of death within the scheduled treatment period (OR 0.78, CI 0.58/1.06), which was significant for ischemic stroke (OR 0.65, CI 0.44/0.97) and for truly randomized studies (OR 0.69, CI 0.47/1). No significant result, however, was obtained for long-term outcome. The drug had almost no side effect (another point of superiority as compared with steroids!). We know that glycerol is almost never used in the Anglo-Saxon and Scandinavian countries, but it is, however, still popular in Italy, Poland, and China. Since a trial should include at least 2000 people to have enough power to detect a clinically significant effect on long-term outcome, we are discussing with the Italian stroke patient association (ALICE) the possibility of such an independent study; however, a possible international collaboration is seen with interest. Those who want to read the first draft of the protocol can write to us.

Stefano Ricci, MD
Maria Grazia Celani, MD
Enrico Righetti, MD
Servizio Aziendale per le Malattie Cerebrovascolari
Perugia, Italy

New Trial(s) on Antiedema Treatment in Stroke?
Stefano Ricci, Maria Grazia Celani and Enrico Righetti

Stroke. 2004;35:e93; originally published online March 25, 2004;
doi: 10.1161/01.STR.0000125306.61072.7e
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/35/5/e93

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/